Andrew Mahon
Nanometics LLC
Affiliations
Albert Einstein College of Medicine
New York University
Technologies
Therapeutic
Indication
Autoimmune & Inflammation
Clinical Research
Clinical Trials
Drug Discovery
Oncology
Orphan Diseases
Website
nanometicslab.comWe are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer.
